Mol Metab · 2018
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
The discovery-to-proof-of-concept study characterising LY3298176 (tirzepatide) as a novel dual GIP/GLP-1 receptor agonist.
View on PubMed (PMID 30473097)